Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes
Charlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Mark Wilson, Katrina Gatley, Anita Chhabra, M Loredana Marcovecchio, A Emile J Hendriks, Hilde Morobé, Piotr Jaroslaw Chmura, Simon Bond, Bärbel Aschemeier-Fuchs, Mikael Knip, Timothy Tree, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Michael J Haller, Almut Nitsche, Anke M Schulte, Chantal Mathieu, Adrian Mander, David Dunger
BMJ Open Dec 2021, 11 (12) e053669; DOI: 10.1136/bmjopen-2021-053669